Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from GT Biopharma ( (GTBP) ).
On May 7, 2025, GT Biopharma‘s board of directors expanded from four to six members, appointing Hilary Kramer and Andrew Ritter as non-employee directors. Following the resignations of Bruce Wendel and Rajesh Shrotriya, the board reduced its size back to four members on May 12, 2025, with Kramer and Ritter taking key roles in the company’s committees.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
GT Biopharma, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutics for the treatment of cancer and other diseases.
Average Trading Volume: 477,313
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.83M
For detailed information about GTBP stock, go to TipRanks’ Stock Analysis page.